COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
Jaguar Health, Inc. to discuss Phase 3 OnTarget trial results for metastatic breast cancer subgroup. Focus on orphan population and expanded access program. Virtual fireside chat with CEO Lisa Conte on June 10, 2025 -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
Jaguar Health's Napo Pharmaceuticals shares plans to seek approval for crofelemer in cancer therapy-related diarrhea for metastatic breast cancer patients. Key discussions with FDA highlighted in Type C Meeting -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series
Jaguar Health's CEO Lisa Conte will participate in a virtual fireside chat on June 10, 2025 to discuss the company's orphan disease development programs
